50 results
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its
424B5
TRML
Tourmaline Bio Inc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
limitations including suboptimal efficacy, lack of durable efficacy, high burden dosing profile, and an unknown long-term safety profile. We believe TOUR006 … for a differentiated product profile for the treatment of TED based on the literature supporting IL-6 pathway inhibition in active TED, a favorable long-term safety
424B5
juvqbo3zjiujj5nt5pgx
24 Jan 24
Prospectus supplement for primary offering
9:20pm
8-K
EX-99.1
129eh
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.2
1dmsx nvyucb
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
zx96g3
8 Jan 24
Regulation FD Disclosure
9:19am
425
ysqvd0nayu5 eoovkzyu
26 Sep 23
Business combination disclosure
8:24am
8-K
EX-99.1
x9pfgrmmv fpj0
26 Sep 23
Regulation FD Disclosure
8:21am
424B3
fcov9frnsv4lx75 9r
15 Sep 23
Prospectus supplement
6:31am
425
4ko7 u6m4ib
13 Sep 23
Business combination disclosure
9:14am
8-K
EX-99.1
n0i3a qjnh0f3bt910
13 Sep 23
Regulation FD Disclosure
9:13am
S-4/A
yzq1d3
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
vd9zk127
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm